|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer Statistics 2009. CA Cancer J Clin. 59:1–25. 2009.
View Article : Google Scholar
|
|
2
|
Hung KE and Chung DC: New insights into
the molecular pathogenesis of colorectal cancer. Drug Discov Today
Dis Mech. 3:439–445. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Glass CK and Rosenfeld MG: The coregulator
exchange in transcriptional functions of nuclear receptors. Genes
Dev. 14:121–141. 2000.PubMed/NCBI
|
|
4
|
Kliewer SA, Sundseth SS, Jones SA, Brown
PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard
JM and Lehmann JM: Fatty acids and eicosanoids regulate gene
expression through direct interactions with peroxisome
proliferator-activated receptors alpha and gamma. PNAS.
94:4318–4323. 1997. View Article : Google Scholar
|
|
5
|
Matthiessen MW, Pedersen G, Albrektsen T,
Adamsen S, Fleckner J and Brynskov J: Peroxisome
proliferator-activated receptor expression and activation in normal
human colonic epithelial cells and tubular adenomas. Scand J
Gastroenterol. 40:198–205. 2005. View Article : Google Scholar
|
|
6
|
Su WD, Bush CR, Necela BM, Calcagno SR,
Murray NR, Fields AP and Thompson EA: Differential expression,
distribution, and function of PPARγ in the proximal and distal
colon. Physiol Genomics. 30:342–353. 2007.
|
|
7
|
Schwab M, Reynders V, Loitsch S, Shastri
YM, Steinhilber D, Schröder O and Stein J: PPARγ is involved in
mesalazine-mediated induction of apoptosis and inhibition of cell
growth in colon cancer cells. Carcinogenesis. 29:1407–1414.
2008.
|
|
8
|
Eng C: PTEN: one gene, many syndromes. Hum
Mutat. 22:183–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nassif NT, Lobo GP, Wu X, Henderson CJ,
Morrison CD, Eng C, Jalaludin B and Segelov E: PTEN mutations are
common in sporadic microsatellite stable colorectal cancer.
Oncogene. 23:617–628. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Song MS, Salmena L, Carracedo A, Egia A,
Lo-Coco F, Teruya-Feldstein J and Pandolfi PP: The
deubiquitinylation and localization of PTEN are regulated by a
HAUSP-PML network. Nature. 455:813–817. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lobo GP, Waite KA, Planchon SM, Romigh T,
Nassif NT and Eng C: Germline and somatic cancer-associated
mutations in the ATP-binding motifs of PTEN influence its
subcellular localization and tumor suppressive function. Hum Mol
Genet. 18:2851–2862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rahman MA, Dhar DK, Yamagicgi E, Maruyama
S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H and Nagasue N:
Coexpression of inducible nitric oxide synthase and COX-2 in
hepatocellular carcinoma and surrounding liver: possible
involvement of COX-2 in the angiogenesis of hepatitis C
virus-positive cases. Clin Cancer Res. 7:1325–1332. 2001.
|
|
13
|
Nagata D, Yoshihiro H, Nakanishi M,
Naruyama H, Okada S, Ando R, Tozawa K and Kohri K: Peroxisome
proliferator-activated receptor-gamma and growth inhibition by its
ligands in prostate cancer. Cancer Detect Prev. 32:259–66. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato H, Ishihara S, Kawashima K, Moriyama
N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N
and Kinoshita Y: Expression of peroxisome proliferator-activated
receptor (PPAR) γ in gastric cancer and inhibitory effects of PPARγ
agonists. Br J Cancer. 83:1394–1400. 2000.
|
|
15
|
Sun WH, Chen GS, Ou XL, Yang Y, Luo C,
Zhang Y, Shao Y, Xu HC, Xiao B, Xue YP, et al: Inhibition of COX-2
and activation of peroxisome proliferator-activated receptor gamma
synergistically inhibits proliferation and induces apoptosis of
human pancreatic carcinoma cells. Cancer Lett. 275:247–255. 2009.
View Article : Google Scholar
|
|
16
|
Chen D, Jin GF, Wang Y, Wang H, Liu H, Liu
Y, Fan W, Ma H, Miao R, Hu Z, et al: Genetic variants in peroxisome
proliferator-activated receptor-γ gene are associated with risk of
lung cancer in a Chinese population. Carcinogenesis. 29:342–350.
2008.
|
|
17
|
Mansen A, Guardiola-Diaz H, Rafter J,
Branting C and Gustafsson JA: Expression of the peroxisome
proliferators-activated receptor (PPAR) in the mouce colonic
mucosa. Biochem Biophys Res Commun. 222:844–851. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fujisawa T, Nakajima A, Fujisawa N,
Takahashi H, Ikeda I, Tomimoto A, Yonemitsu K, Nakajima N, Kudo C,
Wada K, et al: Peroxisome proliferator-activated receptor gamma
(PPARgamma) suppresses colonic epithelial cell turnover and colon
carcinogenesis through inhibition of the beta-catenin/T cell factor
(TCF) pathway. J Pharmacol Sci. 106:627–38. 2008. View Article : Google Scholar
|
|
19
|
Eun CS, Han DS, Lee SH, Paik CH, Chung YW,
Lee J and Hahm JS: Attenuation of colonic inflammation by PPARγ in
intestinal epithelial cells: effect on toll-like receptor pathway.
Dig Dis Sci. 51:693–697. 2006.
|
|
20
|
Feilchenfeldt J, Brundler MA, Soravia C,
Totsch M and Meier CA: Peroxisome proliferators-activated receptors
(PPARs) and associated transcription factors in colon cancer:
reduced expression of PPARgamma-coactivator 1 (PGC-1). Cancer Lett.
203:25–33. 2004. View Article : Google Scholar
|
|
21
|
Hisatake J, Ikezoe T, Carey M, Holden S,
Tomoyasu S and Koeffler HP: Down-regulation of prostate-specific
antigen expression by ligands for peroxisome proliferator-activated
receptor gamma (troglitazone) in human prostate cancer. Cancer Res.
19:5494–5498. 2000.
|
|
22
|
Puzio-Kuter AM, Martin MC, Kinkade CW,
Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C and Abate-Shen C:
Inactivation of p53 and Pten promotes invasive bladder cancer.
Genes and Dev. 23:675–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iwanaga K, Yang YN, Raso MG, Ma L, Hanna
AE, Thilaganathan N, Moghaddam S, Evans CM, Li H, Cai WW, et al:
Pten inactivation accelerates oncogenic K-ras-initiated
tumorigenesis in a mouse model of lung cancer. Cancer Res.
68:1119–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loupakis F, Pollina L, Stasi I, Ruzzo A,
Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E,
et al: PTEN expression and KRAS mutations on primary tumors and
metastases in the prediction of benefit from cetuximab plus
irinotecan for patients with metastatic colorectal cancer. J Clin
Oncol. 27:2622–2629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou XP, Loukola A, Salovaara R,
Nystrom-Lahti M, Peltomaki P, De la Chapelle A, Aaltonen LA and Eng
C: PTEN mutational spectra expression levels and subcellular
localization in microsatellite stable and unstable colorectal
cancers. Am J Pathol. 161:439–447. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lobo GP, Waite KA, Planchon SM, Romigh T,
Houghton JA and Eng C: ATP modulates PTEN subcellular localization
in multiple cancer cell lines. Hum Mol Genet. 17:2877–2885. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bowen KA, Doan HQ, Zhou BP, Wang Q, Zhu Y,
Rychahou PG and Evers BM: PTEN loss induces epithelial-mesenchymal
transition in human colon cancer cells. Anticancer Res.
29:4439–4449. 2009.PubMed/NCBI
|
|
28
|
Rychahou PG, Kang JH, Gulhati P, Doan HQ,
Chen LA, Xiao SY, Chung DH and Evers BM: Akt2 over expression plays
a critical role in the establishment of colorectal cancer
metastasis. PNAS. 105:20315–20320. 2008. View Article : Google Scholar : PubMed/NCBI
|
